Showing posts with label Gilead Stock. Show all posts
Showing posts with label Gilead Stock. Show all posts

Saturday, December 15, 2012

Remove industry bias from clinical trials before it's too late

Here's an article from several researchers at the Univ. of New South Wales and the Univ. of Sydney, debunking self-serving GlobalBigPharma-funded clinical trials of all kinds of drugs:

They use Tamiflu as an example--the worthless "flu" palliative peddled by our friends at Gilead Sciences, the biggest purveyors of the toxic "HIV-ARV" chemo. 
Gildead's Gilead’s CEO Martin Joins “$50 Million 
And speaking of Gilead Sciences, I am eagerly awaiting Gilead's 2012 annual report, to place a dollar-value on Gilead CEO John C. Martin's iatrogenic illness-producing greed. Here is a HAART-warming web page displaying the warfare inside the HIV-AIDS Drug Industrial Complex, in which the federal tax dollar-sucking AIDS Healthcare Foundation (AHF) of Los Angeles attacks Martin, one of the ten highest paid CEO's in America, according to Forbes. 

Apparently Martin's pay-package is so high that it affects the AHF pharmacies' bottom line. AHF seems to be fishing for a lower price for Truvada, Atripla and the other Gilead poison AHF buys from Gilead. Martin and AHF don't seem to think they are getting rich enough on the backs of the vulnerable gay and black millions who have been caught in the $12,000-$14,000/year AIDS Drug death trap.

G'day,
--Terry Michael

P.S. Unfortunately, if you dig deeper into www.theconversation.edu.au you'll find that this Aussie effort to think outside the usual peer-reviewed journal box produces little or no skepticism about the SEX=HIV=AIDS=DEATH paradigm. I am trying to sign up to contribute writing at the site, but I suspect academic freedom to think non-knowledge-monopoly thoughts will be no more tolerated Down Under than it is in the U.S., under HIV Czar J. Edgar Fauci.

Saturday, November 17, 2012

Gilead Presents Encouraging Data - HIV therapy Stribild

FOLLOW THE MONEY

Posted
11/16/2012 1:00 PM
 by Zacks Equity Research


Gilead Sciences(GILD) recently presented encouraging long-term data on its HIV therapy Stribild from two ongoing phase III studies (102 and 103) as a first-line therapy. Data from study 102 revealed that Stribild was non-inferior to Gilead's Atripla after two years of treatment.

Data from study 103 demonstrated the non inferiority of Stribild to Norvir (ritonavir)-boosted Reyataz plus Truvada after a similar time period. While Norvir is marketed byAbbott Labs(ABT), Reyataz is marketed byBristol-Myers Squibb(BMY). Gilead presented the encouraging results at the 11th international congress on drug therapy regarding HIV infection in the UK.

We note that Stribild, a combination pill, is a new addition to Gilead's formidable HIV franchise. The drug was approved by the US Food and Drug Administration (FDA) in August 2012 as a first-line therapy for treating adults suffering from HIV. The approval was based on encouraging 48 weeks data from studies 102 and 103. Stribild is under review for the same indication in the EU.

Neutral on Gilead

We currently have a Neutral recommendation on Gilead. The stock carries a Zacks #3 Rank (Holdrating) in the short run. We remain optimistic on the growth prospects of Gilead's HIV drugs, Truvada and Atripla. We are also encouraged by the sales ramp of Complera/Eviplera, which together with Stribild, has further fortified the HIV franchise and helped to mitigate the impact of upcoming patent expirations.

Gilead is looking to combat the threat of genericization by inking deals, making acquisitions and introducing new products. To further strengthen its hepatitis C virusportfolio, Gilead purchased Pharmasset earlier in the year, for approximately $11.1 billion.

Tuesday, September 4, 2012

The Shame of Gilead

by Terry Michael


Gilead Sciences, headquartered in Foster City, CA, is the world's number one purveyor of the chemotherapies known as "anti-retrovirals" (ARVs.) In 2011, the company (named for the Biblical "balm of Gilead") reported ARV sales of about $6.91 billion dollars. The trade names for their ARVs are: Truvada, Atripla, Viread, Complera and Emtriva--all of which they acknowledge have serious adverse "side" effects (as noted in the Gilead prescribing information for Truvada.) Gilead was way ahead of nearest competitor Bristol-Myers-Squibb, which sold about $3.05 billion of the chemo in 2011, according to year-end corporate reports I have reviewed.

Friday, February 3, 2012

Gilead Sciences 4Q profit rises on HIV drug sales

www.cbsnews.com
(AP)  FOSTER CITY, Calif. — Gilead Sciences Inc.'s profit grew 6 percent in the fourth quarter on greater sales of its HIV drugs including Atripla.

Gilead said Thursday that its profit rose to $665.1 million, or 87 cents per share, from $629.4 million, or 76 cents per share, one year ago. Excluding acquisition, restructuring, and stock-based compensation expenses, Gilead said it earned 97 cents per share, far short of analyst estimates for $1.05.

Wednesday, June 1, 2011

History of Gilead Sciences makers of "treatments of HIV"

Some interesting reading, (well with Wikipedia sometimes you do have to read with between the lines). Still, who's been on the Broad and when...good to know who's mixing up all the HIV meds formulas uh?


Gilead Sciences (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes therapeutics. For many years since the company was founded, the company concentrated primarily on antiviral drugs to treat patients infected withHIV, hepatitis B or influenza. In 2006, Gilead acquired two companies that were developing drugs to treat patients with pulmonarydiseases. The company has fourteen commercially available products. Headquartered and founded in Foster City, California, Gilead has operations in North America, Europe and Australia. As of the end of 2009, the company had approximately 4,000 full-time employees.The company's name and logo refer to the Balm of Gilead. Gilead (a place mentioned in the Bible) was famed for its small trees that produced a resin used in medicine.
Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.

History

Gilead Sciences was originally formed at Menlo Ventures under the name of "Oligogen, Inc." in August 1987 by H. DuBose Montgomery, co-founder of Menlo Ventures and Michael L. Riordan, a medical doctor who was 29 years old at the time. Riordan graduated from the Johns Hopkins University School of Medicine, spent a year as a consultant and then joined as an associate at Menlo Ventures in 1986. The company traces its roots to a runny nose because Montgomery got a particularly bad cold—a virus—and in his misery he wondered why so few antivirals existed when so many antibiotics were in use. The name of the company was changed to "Gilead Sciences" in 1988 and Montgomery served as the first Chairman of the Board from 1987 to 1993. Riordan looked to Donald Rumsfeld as a mentor in the business world and to navigate the political waters. Under the technical leadership of scientist Mark Matteucci, the company focussed on discovery research, making small strands of DNA (oligomers) to assess the potential of genetic code blockers (gene therapy). Its development of small molecule antiviral therapeutics was ushered in by John Martin in 1992 with the licensing of nucleotide compounds discovered in two European academic labs.

Thursday, April 21, 2011

Gilead U.S. AIDS drug sales fall short of estimates

LOS ANGELES | Wed Apr 20, 2011 8:44pm EDT

Reuters) - Gilead Sciences Inc's (GILD.O) first-quarter profit fell a deeper-than-expected 24 percent as U.S. state-funded purchases of its core AIDS drugs were lower than expected and royalty revenue slipped.
The company's shares dropped more than 3 percent in after-hours trading.
Sales of HIV drug Truvada rose 2 percent to $673.1 million, while sales of Atripla rose 7 percent to $744.5 million -- but the totals fell short of respective average analyst estimates of $688 million and $793 million.
Gilead said U.S. sales were hit by temporary cutbacks at state-funded AIDS drug assistance programs (ADAPs) in Florida and Texas.